Valneva’s stock has risen in recent days on positive vaccine data.
The latest study results from Valneva look promising: according to these results, the Covid-19 vaccine from the French-Austrian company showed better immune protection than that from Astra-Zeneca in a clinical phase 3 study with more than 4000 participants.
In addition, subjects 30 years of age and older reported significantly fewer adverse events compared to Astra-Zeneca up to seven days after vaccination, both in terms of injection site reactions and immune system reactions.
In New York, the stock was last quoted at 44.84 dollars. On Thursday, Valneva was up a whopping 6.79 percent. At the weekly glance, the stock is up a whopping 59.86 percent. The all-time high was reached on August 30 and was $59.15.
The current studies pave the way for Valneva to file for regulatory approval. A corresponding application for the EU is being prepared, the company said. Further price rises are to be expected if the company continues to be successful.
For more updates, follow us on Twitter:@JRC_Capital
